Ridogrel (standaard)

Ridogrel (Standard) is the analytical standard of Ridogrel. This product is intended for research and analytical applications. Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities[1][2][3].

110140-89-1

12352100

Prostaglandin Receptor; Reference Standards

GPCR/G Protein; Others

Inflammation/Immunology

O=C(O)CCCCO/N=C(C1=CC=CN=C1)\C2=CC=CC(C(F)(F)F)=C2

C18H17F3N2O3

366.33

[1]De Clerck F, et al. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo. Thromb Haemost. 1989;61 (1) :43-49.|[2]Di Perri T, et al. Ridogrel, una nuova molecula antiaggregante piastrinica a doppio meccanismo d'azione. Profilo farmacologico e clinico [Ridogrel, a new platelet antiaggregant molecule with a double mechanism of action. A pharmacological and clinical profile]. Recenti Prog Med. 1991;82 (10) :533-540.|[3]Carty E, et al. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14 (6) :807-817.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-A0221R/

Reference Standards